Anti-Neprilysin are peptidases that degrade neprilysin and other peptides in the brain and periphery. Neprilysin inhibitors are used for the treatment of heart failure and hypertension by preventing the degradation of natriuretic peptides which mediate vasodilation and natriuresis. The global Anti-Neprilysin Market is estimated to be valued at US$ 1,263.3 Mn in 2023 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends: Emerging therapeutic applications of anti-Neprilysin drugs are expected to drive the market growth over the forecast period. Anti-Neprilysin drugs are being studied for the treatment of several other conditions besides heart failure like acute heart failure, hypertension, and chronic kidney disease. Ongoing clinical trials are exploring the efficacy of anti-Neprilysin drugs in reducing cardiovascular risk in patients with diabetes. This wide therapeutic potential is projected to boost the adoption of anti-Neprilysin drugs, thereby fueling the market growth.
Segment Analysis
The global anti-Neprilysin market can be segmented based on drug class, distribution channel and region. Based on drug class, the sacubitril/valsartan segment is projected to dominate the market during the forecast period. Sacubitril/valsartan is currently the only approved neprilysin inhibitor in the market and has shown promising results in reducing cardiovascular mortality and morbidity in patients with heart failure.
Key Takeaways
The global anti-Neprilysin market is expected to witness high growth over the forecast period of 2023-2030. The market is projected to grow at a CAGR of 4.6% during the forecast period to reach a valuation of US$1,263.3 Mn by 2024.
Regional analysis: North America is expected to dominate the anti-Neprilysin market during the forecast period. Higher healthcare expenditure, growing geriatric population and rising prevalence of heart failure are some of the major factors boosting market growth in the region. Europe is also expected to account for a significant share of the global market due to growing research activities in the field of heart failure treatment. However, Asia Pacific is projected to witness the highest growth during the forecast period owing to improving healthcare infrastructure and rising awareness regarding cardiovascular diseases.
Key players operating in the anti-Neprilysin market are BIOPROJET, Novartis AG, Pharmaleads SA, Theravance Biopharm, Cipla Inc, Oceanic Pharmachem Pvt. Ltd. Novartis AG dominates the market with its patented drug sacubitril/valsartan approved for the treatment of heart failure. Other players are focusing on developing novel neprilysin inhibitors through structured drug design to expand their product offerings. Partnerships and collaborations are also expected among players to strengthen their research capabilities.
No comments:
Post a Comment